Biomea Fusion Inc BMEA

$1.27 -0.03 (-2.31%)

Valuation

Market cap
92,055,000
Revenue TTM
$0
Net income TTM
$-61,800,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
844,300
Avg volume
1,691,394
Day's range
$1.26 – $1.31
Shares out
72,484,000
Stochastic %K
4%
Beta
-0.28
Analysts
Strong Sell
Price target
$7.00

Price

Company profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of i...

Show more

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 980 9099
Website
https://biomeafusion.com
Address
1599 Industrial Road, San Carlos, United States

Latest news

Stocktwits

Rosalie1224 Oct 3, 4:39 PM
$BMEA Lead drug icovamenib targets Type 1/Type 2 diabetes..,.
1 replies
JC_254 Oct 3, 3:30 PM
$BMEA 🦗 🦗
0 replies
Dcvfin Oct 3, 11:56 AM
$BMEA now we wait for the news to drop Im guessing late in the month as these guys seem to want to drag their feet Wish management was better even for a little biotech as their drug has so much potential
1 replies
septrading Oct 2, 9:30 PM
$BMEA I've been keeping GPT-6 Astra "Very High" up to date on all the developments, including BMEA, KURA/Caspian, and the Lilly combination news, etc. It was time to update the model. First, it hovered around 1.28 all week; it's a significantly different picture now for the warrant conversion/yield. Using the same base case and tiered placebo-adjusted efficacy, we get a drastic reduction in the initial trading ranges compared to the 9/15 model which followed Erdtmann's bullish presentation and confirmation of the Q3 Data. Now, the base case has gone from 3.35-5.20 (Sept. 15th numbers in red) down to 1.60-2.40 (today's model in green). That assumes, as before, only a 5-5.5 weight loss. Interestingly, the trading-after ranges perform better once you clear the base-case results. Trying to remain bullish, and the model isn't popping that bubble yet.
4 replies
monstertrades1 Oct 2, 8:38 PM
$BMEA $7 price target
1 replies
monstertrades1 Oct 2, 8:38 PM
$BMEA "Citizens reiterates Biomea Fusion stock rating on menin inhibitor validation" "Citizens reiterated a Market Outperform rating and $7.00 price target on Biomea Fusion Inc. (NASDAQ:BMEA) shares" https://ng.investing.com/news/stock-market-news/citizens-reiterates-biomea-fusion-stock-rating-on-menin-inhibitor-validation-93CH-2715471
0 replies
IM11 Oct 2, 8:19 PM
$BMEA The way big money is treating VKTX, GPCR, and KLRA (leading biotech obesity drugs in Phase 3), even if BMF-650 results are AMAZING, not sure big money is gonna care based on the lack of interest in the whole segment at the moment. Those 3 have lost 30-50% in the last 2 months and VKTX and GPCR dropped on GOOD DATA! So hopefully not the case here because it is so under-valued, but just to put things in perspective.
1 replies
monstertrades1 Oct 2, 7:59 PM
$BMEA Added $20K into next week, LOTTO
1 replies